Dyadic International (DYAI)
NASDAQ:DYAI
DYAI Stock Chart & Stats
$0.93
-$0.19(-9.79%)
At close: 4:00 PM EST
$0.93
-$0.19(-9.79%)
Day’s Range― - ―
52-Week Range$0.65 - $1.43
Previous CloseN/A
Volume131.09K
Average Volume (3M)396.96K
Market Cap
$31.05M
Enterprise Value$33.55M
Total Cash (Recent Filing)$7.32M
Total Debt (Recent Filing)$7.12M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
May 20, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding36,438,700
10 Day Avg. Volume144,364
30 Day Avg. Volume396,964
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)24.88
Price to Sales (P/S)9.92
P/FCF Ratio-5.38
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue10.86
Enterprise Value/Gross Profit13.48
Enterprise Value/Ebitda-4.70
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.06
Revenue Forecast (FY)$8.47M
Bulls Say, Bears Say
Bulls Say
Platform Validation Via CollaborationsExternal validation by Gates, CEPI, NIAID, Scripps, Oxford and multiple academic partners materially reduces technical and adoption risk. Durable third-party proof points make licensing and partnership discussions easier, supporting sustained platform licensing, milestone and royalty revenue over quarters as partners progress.
Commercial Product Launches And Channel PartnershipsCommercial launches (recombinant albumin, DNase I, FGF) plus distribution and OEM partners create initial recurring sales channels and scale without large capex. Profit-sharing and distributor models sustainably shift revenue mix toward repeat orders and recurring product sales as customers qualify offerings.
Non-dilutive Grant Funding And Runway ExtensionMaterial grant receipts provide non-dilutive development capital and reduce near-term financing pressure, enhancing runway into 2027. This durable funding supports product commercialization and partner programs, lowering urgent dilution risk while the company executes a gradual revenue ramp.
Bears Say
Sharply Increased LeverageRapidly rising debt relative to a shrinking equity base materially weakens the balance sheet. High leverage limits financial flexibility, raises refinancing and covenant risk, and increases the likelihood that future capital raises will dilute shareholders or prioritize debt servicing over growth investments.
Persistent Negative Operating Cash FlowThe business does not yet self-fund operations; recurring negative cash flow forces reliance on external financing, grants, or partner payments. Over 2-6 months this constrains pace of commercialization, heightens dilution risk if equity is issued, and limits ability to scale manufacturing or sales investments.
Revenue Decline And Slow Product RampRevenue shrinkage and a shift toward grant and partner-driven income indicate product sales are still nascent. Customer qualification timelines and pricing sensitivity mean recurring, high-volume revenue will ramp slowly, delaying margin scalability and prolonging reliance on grants and milestone payments.
Dyadic International News
DYAI FAQ
What was Dyadic International’s price range in the past 12 months?
Dyadic International lowest stock price was $0.65 and its highest was $1.43 in the past 12 months.
What is Dyadic International’s market cap?
Dyadic International’s market cap is $31.05M.
When is Dyadic International’s upcoming earnings report date?
Dyadic International’s upcoming earnings report date is May 20, 2026 which is in 47 days.
How were Dyadic International’s earnings last quarter?
Dyadic International released its earnings results on Mar 25, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.045 by $0.005.
Is Dyadic International overvalued?
According to Wall Street analysts Dyadic International’s price is currently Overvalued.
Does Dyadic International pay dividends?
Dyadic International does not currently pay dividends.
What is Dyadic International’s EPS estimate?
Dyadic International’s EPS estimate is -0.04.
How many shares outstanding does Dyadic International have?
Dyadic International has 36,438,700 shares outstanding.
What happened to Dyadic International’s price movement after its last earnings report?
Dyadic International reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.045. Following the earnings report the stock price went down -19.61%.
Which hedge fund is a major shareholder of Dyadic International?
Currently, no hedge funds are holding shares in DYAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
DYAI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful operational progress: multiple product launches, distribution and manufacturing partnerships, grant funding, and platform validation through reputable collaborators, signaling a substantive transition toward commercialization. However, near-term financials show declining revenue (-11.7%) and larger losses (+~26.7% net loss increase), with continued cash burn and dependence on partner/grant-driven revenue. Management presents a credible path to scale and a runway into 2027 but acknowledges a measured, gradual revenue ramp as customers qualify products; the strategic progress and non-dilutive funding moderately outweigh short-term financial headwinds.View all DYAI earnings summariesDYAI Stock 12 Month Forecast
Average Price Target
―Technical Analysis
―
Collplant Holdings
―
Reviva Pharmaceuticals Holdings
―
―
Rani Therapeutics Holdings
―
Ownership Overview
16.43% Insiders
2.75% Mutual Funds
8.59% Other Institutional Investors
69.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---